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Abstract 
Globally, IVF patients are routinely offered and charged for a selection of adjunct 
treatments and tests or ‘add-ons’ that they are told may improve their chance of a 
live birth, despite there being no clinical evidence supporting the efficacy of the add 
on.  Any new IVF technology claiming to improve live birth rates (LBR) should, in 
most cases, first be tested in an appropriate animal model, then in clinical trials, to 
ensure safety, and finally in a randomized controlled trial (RCT) to provide high 
quality evidence that the procedure is safe and effective.  Only then should the 
technique be considered as ‘routine’ and only when applied to the similar patient 
population as those studied in the RCT. Even then, further paediatric and long-term 
follow up studies will need to be undertaken to examine the long-term safety of the 
procedure.  Alarmingly, there are currently numerous examples where adjunct 
treatments are used in the absence of evidence-based medicine and often at an 
additional fee.  In some cases, when RCTs have shown the technique to be 
ineffective, it is eventually withdrawn from the clinic.  In this paper, we discuss some 
of the adjunct treatments currently being offered globally in IVF laboratories including 
embryo glue and adherence compounds, sperm DNA fragmentation, time lapse 
imaging, preimplantation genetic screening, mitochondria DNA load measurement 
and assisted hatching and examine the evidence for their safety and efficacy in 
increasing LBRs.  We conclude that robust studies are needed to confirm the safety 




IVF is a globally adopted technique supporting an extremely lucrative medical 
industry which has revolutionized human reproduction by offering hope of a family 
where none existed before. Patients routinely pay large sums of money for treatment 
and many are willing to try anything that might help them improve their chances of 
having a baby. 
The vast majority of IVF clinics want to help their patients achieve this objective as 
much as possible which may involve undertaking unproven procedures and tests 
supported by anecdotal, low quality or unpublished evidence.  In the last decade, a 
plethora of adjuncts or ‘add-ons’ have been introduced, many without any robust 
evidence that they increase the chances of a live birth or have any tangible benefit in 
terms of the health and wellbeing of the offspring (Nardo et al., 2009, Datta et al., 
2015, Spencer et al., 2016, Harper and Brison, 2013).   
The requirement that patients give informed consent to adjunct treatment in IVF, 
whilst necessary, may be insufficient to eliminate the over-selling or mis-selling of 
adjunct therapies for which the evidence of efficacy is poor or non-existent. In the 
UK, the Human Fertilisation and Embryology (HFEA) Act 1990, as amended, 
requires patients to ‘be provided with such relevant information as is proper’ before 
embarking on treatment (Human Fertilisation and Embryology Act 1990, sch. 3, para. 
3(1)(b)). Patients should also be provided with ‘a personalised cost treatment plan’ 
(HFEA Code of Practice, para 4.3). Before an adjunct treatment is offered, the 
legislation requires clinics to provide open and honest information about the 
existence of robust evidence to support the particular intervention, along with 
information about costs. However, the ‘therapeutic illusion’ (Casarett, 2016), which 
commonly involves ‘unjustified enthusiasm for treatment on the part of both patients 
and doctors’ (Thomas, 1978), may mean that patients are not necessarily put off by 
low success rates or underpowered trial data, especially when simplistic 
explanations for reproductive failure circulate online and in the popular press.  For 
example, a clinician might explain that the studies of immune therapy in assisted 
reproduction treatments to date have been poorly designed and that larger RCTs are 
necessary (Nardo et al, 2015), while patients might read newspaper articles with 
headlines such as ‘The killer cells that robbed me of four babies’ (Barber, 2011). 
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All IVF clinics need to consider the safety and efficacy of new technologies before 
introducing them and beginning to charge patients.  In most cases, this should 
include preliminary work on animal models, followed by studies on human embryos 
donated for research and finally well designed RCTs with a follow up of all children 
born from the procedure (Harper et al., 2012).  If such preliminary studies are not 
published, it is possible that technology bringing no clinical benefit or even leading to 
adverse health outcomes may be introduced.   
There are several key factors affecting the validity and usefulness of any RCT 
performed for IVF. Validity can be assessed through risk of bias (Higgins et al., 
2011) whereas the usefulness depends on the definition of the patient cohorts, the 
interventions compared, the primary outcome and the number of participants. 
Typically, demonstrating a clinical benefit will require many more participants than 
that required to demonstrate physiological effects. 
Wilkinson et al (2016) analysed 142 IVF RCTs published in 2013 and 2014.   They 
found that no consistent outcome measure was used.  They suggest that initiatives 
to standardize outcome such as LBR or cumulative LBR should be encouraged. 
Trials using implantation rate or clinical pregnancy rate (CPR) as outcome measures 
are only appropriate for preliminary studies.  After any technique is brought into 
routine clinical practice, follow up longitudinal studies should be undertaken to 
ensure the safety and efficacy of the intervention. 
In 2009, the Policy and Practice Committee of the British Fertility Society reported on 
medical adjuncts in IVF and concluded that “there is a need for good clinical trials in 
many of the areas surrounding medical adjuncts in IVF to resolve the 
empirical/evidence divide” (Nardo et al., 2009). Datta et al. (2015) reported on 
clinical and laboratory adjuncts and tests in IVF and stated that properly powered 
RCTs are more valuable than a meta-analysis of a number of small heterogeneous 
RCTs.  Spencer et al. (2016) carried out an audit of UK based IVF clinic web sites 
and found that many were offering patients a large number of unproven adjuncts at 
additional cost.   
In this paper we describe some of the adjunct IVF laboratory treatments and tests 
that are currently being offered globally (Table 1), often at a substantial cost for the 
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patient. We describe the techniques and discuss the evidence for their safety and 
whether they increase LBR.  The majority of the adjunct treatments listed here are 
included in the HFEA’s recent addition to their website where they list evidence for 
‘add-on’ treatments (due to go live in February 2017).  Laboratory adjuncts that we 
could have been included but were not due to space limitations are; intracytoplasmic 
sperm injection (ICSI) for non male infertility patients (Grimstad et al., 2016), 
intracytoplasmic morphologically selected sperm injection (IMSI), in-vitro 
maturation, artificial oocyte activation, augmentation of mitochondria, intrauterine 
culture and elective freeze all embryos strategies.   
Embryo glue and adherence compounds 
The use of fibrin sealants to reduce ectopic pregnancy rate and increase LBRs was 
first proposed by Feichtinger (1990) and the same author published further 
supportive data in 1992.  Despite this early promise, treatment using fibrin sealants 
never demonstrated reliable significant improvement in clinical outcomes and more 
recently, the focus has shifted to the use of a specific embryo transfer medium 
enriched with the glycoprotein hyaluronan (HA).  It is well reported that HA is 
naturally present in the female reproductive tract and endometrium and forms a 
viscous solution which could enhance the embryo transfer (ET) process and prohibit 
embryo expulsion (Bontekoe et al., 2014).  
The published data surrounding the use of adherence compounds are highly varied 
in quality and robustness of study design and as a result, the use of HA 
supplemented media for ET is still regarded as controversial (Bontekoe et al., 2014).   
The latest Cochrane review of 3898 participants from 17 RCTs demonstrated 
moderate quality evidence for an improvement in CPR and LBR, with an associated 
increase in multiple pregnancy rate, when transfer medium was supplemented with 
HA (Bontekoe et al., 2014).  The authors concluded that further high-quality studies 
were required, in particular where an elective single embryo transfer (eSET) 
procedure was performed, in part to alleviate concerns over the reported increase in 
the multiple pregnancy rate.  A more recent RCT by Fancsovits et al., (2015) looked 
at 581 cycles and did not show a benefit in implantation rate, CPR or LBR, but found 
a higher birth weight in the HA group. 
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The reported increase in multiple pregnancy rate is suggestive of a need for clinics 
considering the use of a HA supplemented ET medium not only to re-evaluate their 
eSET policy and closely monitor their multiple pregnancy rate but also to ensure that 
patients are aware, not only of the possible increased chance of pregnancy, but also 
of the increased chance of multiple pregnancy when they are considering the 
number of embryos they wish to transfer. 
The published evidence may be suggestive of a beneficial effect of the use of HA 
supplemented ET media.   Before robust conclusions can be drawn, however, further 
RCTs are needed to evaluate the efficacy of HA as an adherence compound during 
ET with respect to eSET and the possibility to reduce the multiple pregnancy rate.   
Sperm DNA fragmentation  
Many clinics offer all their patients a sperm DNA fragmentation test.  The assays 
include TUNEL (Terminal deoxynucleotidyl transferase dUTP Nick-End Labeling,) 
Comet, SCD (Sperm Chromatin Dispersal) assay, SCSA (Sperm Chromatin 
Structure Assay) and 8OHdG test (Shamsi et al., 2011). There are clear differences 
between assays in terms of the type of DNA damage being measured and their 
relative sensitivity (Smith et al., 2013). However, no particular assay has yet 
emerged as being of greater diagnostic value than any other. Ultimately the purpose 
of such an assay is to indicate which treatments may be contra-indicated for, or 
beneficial to, patients. This requires both diagnostic accuracy for the assay and 
evidence of effectiveness for the treatment(s). If for example the purpose of the 
assay is to determine whether antioxidant therapy is appropriate for the male partner 
then the measurement of 8OHdG is of paramount importance and robust assays to 
assess this base adduct need to be developed and optimized (Muratori et al., 2015).      
Three recent meta-analyses looked at measuring sperm DNA fragmentation in 
patients undergoing IVF and ICSI.  Osman et al. (2015) performed a meta-analysis 
of six studies and found that, overall, men with low sperm DNA fragmentation had a 
higher LBR than those with high DNA fragmentation, but that the evidence was not 
sufficient to support this when ICSI was used.  They concluded that further RCTs are 
needed to examine the role of ICSI versus IVF for men with high DNA fragmentation.  
Simon et al., (2015) looked at 8068 treatment cycles where DNA damage was 
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measured using all four assays and found a modest but statistically significant 
association of DNA damage with CPR following IVF and/or ICSI.  They found that  
the data varied depending on the assay used.  Cissen et al (2016) performed a 
systematic review and meta-analysis looking at the prognostic value of sperm DNA 
damage measurement, including 30 out of 658 studies. They concluded that current 
tests have limited capacity to predict either the chance of conception after ART or 
which treatment method to choose, and that for now there is insufficient evidence to 
recommend sperm DNA testing. 
The Practice Committee of the ASRM has concluded that ‘current methods for 
assessing sperm DNA integrity do not reliably predict treatment outcomes and 
cannot be recommended routinely for clinical use’ (Pfeifer et al., 2014). 
However a recent Cochrane report observed that low quality evidence suggests that 
antioxidant therapy in the male might increase CPR and LBR in patients where the 
spermatozoa are suffering from oxidative stress (Showell et al., 2014). In this 
context, accurate assessment of 8OHdG levels could be of value in selecting a valid 
patient population.  An RCT investigating the hypothesis that antioxidants can 
reverse oxidative DNA damage in spermatozoa is therefore urgently needed to 
address this possibility.   
Time lapse imaging  
Taking pictures over time and reviewing them as a film, also known as time-lapse 
imaging (TL), is a technique that has been used for a century.  Indeed, the first time 
TL imaging was reported as a tool to visualize early embryonic development was in 
1929 (Lewis and Gregory, 1929). In that report, a remarkably detailed description of 
hamster embryonic development was described and the authors went on to 
speculate whether the observed timings in cleavage rate could predict ”embryonic 
potential”.  More than 50 years later, human embryos were filmed using TL 
technology during their first three days of development (Eriksson et al. 1981). The 
next significant breakthrough was the work by Payne et al. (1997) who used TL 
imaging to describe the first events during fertilization, thus providing insight into how 
diverse and dynamic early embryonic development can be.  
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The first attempt to meaningfully use the unique information from different embryo 
cleavage timings and/or cleavage patterns was performed by Meseguer and 
colleagues in 2011 based on data from 247 embryos known to have implanted 
(Meseguer et al., 2011).  The latest prediction model was published by Petersen et 
al. (2016) but still requires extensive prospective testing and validation.   
The usefulness of TL imaging in human IVF has been well debated.  Among the 
proposed benefits that have been put forward are ”not missing important events 
during culture”, quality control, teaching applications, more information to the patient 
and, of course, an increase in LBR.  
Rubio et al. (2014) conducted the largest RCT to date that included 843 patients 
randomized mainly on day 3 but also on day 5. They reported a 9.7% increase in 
CPR compared to traditional culture and morphology assessments alone.  This effect 
was diluted in the Cochrane review that also included two smaller trials under the 
intention to treat principle.  The authors concluded that “there is insufficient evidence 
of differences in live birth, miscarriage, stillbirth or clinical pregnancy to choose 
between [TL imaging] and conventional incubation” (Armstrong et al., 2015). 
However, more refined models are being continually developed as more data are 
being collected world-wide.  
TL imaging serves so many other functions in the laboratory that its introduction will 
not be held back. It may be unthinkable in 5-10 years to still only be observing 
embryos by manually taking them out and looking at them. TL imaging is a tool 
which confers a number of practical benefits to the IVF laboratory.  The future 
challenge for TL imaging is to find the best role in the IVF laboratory and to reduce 
implementation and consumable costs.  
More RCTs are needed to distinguish whether there are clinical benefits of embryo 
selection algorithms based on TL information leading to an increase in LBR and 
whether there are benefits from uninterrupted embryo culture (Armstrong et al., 
2014). 
Pre-implantation genetic screening  
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When in the 1990s, several studies demonstrated that cleavage stage embryos 
showed a high level of aneuploidy (Coonen et al. 1994, Munne et al., 1995), it was 
postulated that selection against these aneuploid embryos would improve LBRs. It 
was surprising that not only were meiotic abnormalities originating in the oocyte 
found, but also abnormalities occurring postzygotically. As a consequence, many 
embryos were mosaics, containing both normal and aneuploid cells, or several 
different lines of aneuploid cells. Thousands of IVF cycles were performed with 
preimplantation genetic screening (PGS), by biopsying one cell at day 3 and 
performing fluorescent in-situ hybridization (FISH) for five chromosomes. Eleven 
RCTs later, PGS was shown not to increase CPR or LBR and, in some cases, to 
decrease LBR (Harper et al., 2010, Geraedts and Sermon, 2016). It was realized 
that PGS at day 3 was not effective because of the limited accuracy of FISH, the 
limited number of cells available for biopsy, and because at day 3, cleavage stage 
embryos are at a peak of chromosomal abnormality/mosaicism.  
With the advent of new technology allowing comprehensive chromosome screening 
(CCS) of day 5 biopsied trophectoderm cells, PGS is now actively marketed as 
increasing implantation rates, and consequently decreasing time to pregnancy, 
recurrent miscarriages and repeated implantation failure (Sermon et al., 2016).  
Despite these claims, only three RCTs have been published, all of which have been 
criticized because of poor study design. The pilot RCT by Yang et al. (2012) included 
a small sample size of 45 young, good prognosis patients.  Scott et al., (2013) 
performed an RCT on 72 good prognosis patients between the ages of 21 and 42 
years who were randomized quite late, ie. if they had at least two blastocysts 
available for analysis.  Although the authors claimed that PGS increased 
implantation and delivery rates, there was a fundamental methodological flaw in the 
study’s failure to account for the difference between the unit of randomization 
(patients) and unit of analysis (individual embryos). The third RCT studied 89 
patients aiming to compare PGS and SET with the transfer of two embryos (Forman 
et al., 2013). The same methodological problem encountered by the Scott trial was 
introduced and even so, the wide confidence interval for pregnancy did not 
demonstrate a beneficial effect.  
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Currently, two larger RCTs are underway and the results are expected soon. The 
ESTEEM study recruits patients of advanced maternal age and includes analyses of 
polar bodies using array-CGH, while the STAR study recruits all IVF patients and 
uses next generation sequencing on blastocyst biopsies. Other noteworthy 
differences are that the ESTEEM study has an intention-to-treat analysis, while 
STAR includes patients with two analyzable blastocysts as in the Scott and Forman 
studies. Furthermore, the ESTEEM outcome is cumulative LBR, while for STAR it is 
ongoing pregnancy rate after one transfer, an outcome measure that has received 
much criticism and should be abandoned in favour of LBR (Griesinger, 2016).  
Although these studies may serve to provide stronger evidence supporting PGS, the 
current RCTs do not provide sufficiently robust evidence to consider PGS as a 
proven and beneficial treatment. 
Mitochondrial DNA load measurement  
It has been estimated that metaphase II oocytes contain about 105 mitochondrial 
DNA (mtDNA) copies, but since no replication of the mtDNA occurs until the 
blastocyst stage of embryonic development, the mtDNA molecules are divided over 
the cleaving cells (Fragouli and Wells, 2015). In 2015, two papers were published 
reporting an association between higher mtDNA level and lower implantation 
potential in blastocysts (Diez-Juan et al., 2015; Fragouli et al., 2015), pointing to 
disturbed energy provision and metabolic stress in embryos with a higher mtDNA 
content. While the paper of Diez-Juan et al. focused on euploid, transferred 
blastocysts, the other report also showed a relationship between aneuploidy of the 
blastocyst and a higher mtDNA load. According to both reports, euploid embryos that 
implanted after transfer had a mtDNA load below a data-derived threshold. 
Conversely, embryos that failed to implant, or that were aneuploid, showed a wide 
range of mtDNA load. This range overlapped with the implanting embryos at the low 
end, but the level of mtDNA at the high end was much higher in the non-implanting 
embryos. A threshold embryonic mtDNA load above which all embryos failed to 
implant could therefore be identified. Diez-Juan et al reported that 52% (34/65) of the 
embryos below the identified threshold implanted compared to an implantation rate 
across the whole study population of 47% (34/72). For Fragouli et al., these figures 
were 59% (16/27) versus 38% (16/42) respectively. 
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Both groups have initiated an RCT. MitoScore is marketed by the group of Diez and 
is currently tested in RCT NCT02662686 (clinicaltrials.gov). MitogradeTM is marketed 
by Reprogenetics and is being tested in RCT NCT02673125.  
Currently, there is no evidence that selection through mtDNA load measurement 
increases LBR. Application of the technique should therefore strictly be limited to 
participation in either one of RCTs, and this should clearly communicated to the 
patient.  
Assisted hatching 
In 1990, Cohen et al., proposed that making a breach in the zona pellucida may help 
implantation in some patients. Assisted hatching (AH) is usually performed on day 3, 
5 or 6 of embryo development using a non-contact laser, but mechanical or acidic 
solutions have also been used (Balaban et al., 2002).  Clinics use AH for patients of 
advanced maternal age, smokers or patients with a raised FSH, or when transferring 
embryos that have been cryopreserved.  
Three meta-analyses on AH have found a significant increase in CPR but no 
evidence for a difference in LBR.  Martins et al., (2011) found a significant difference 
in CPR using frozen thawed embryos in unselected women and for patients with 
repeated IVF failure, but no evidence of benefit for subgroups of either older women 
or those with a good prognosis.  They concluded that there were too few studies 
looking at LBR to draw conclusions.  The Cochrane review by Carney et al. (2012) 
looked at 31 trials including 1992 clinical pregnancies in 5728 women.  Nine of the 
31 RCTs included data on LBR.  There was no evidence of difference between the 
LBR in the AH and control groups.  Li et al., (2016) looked at 36 RCTs with 6,459 
participants and found that AH gave a significant increase in CPR and multiple 
pregnancy rate but in the 15 RCTs that looked at LBR, there was no evidence of 
difference between the AH and control groups.     
The National Institute for Clinical Excellence (NICE) guidelines (2013) state that 
“assisted hatching is not recommended because it has not been shown to improve 
pregnancy rates”.  
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Duty of care towards the offspring  
Whilst we have considered evidence for increasing the chances of pregnancy and 
live birth, very few interventions in this field have considered the long term health of 
the child. Individual clinics and national and international data collection bodies have 
a duty to evaluate data surrounding the use of adjuncts in IVF and collect long term 
data pertaining to the health of any children born as a result of their use.  
At the individual practitioner level, doctors and scientists recommending an unproven 
procedure to their patients must ensure that they provide comprehensive information 
surrounding the lack of evidence on the safety of the intervention for the resultant 
child.  As best clinical practice dictates that professional guidelines are followed 
when managing patients, adjuncts that have not been proven to be beneficial should 
be used with caution, if used at all.  Furthermore, regulatory bodies could insist that 
any empirical therapy prescribed must be accounted for, ideally with the 
establishment of clinical trials, to ensure long-term maternal and neonatal follow-up.   
Among the techniques described in this paper, it is possible that some could have an 
impact upon the health of the embryo and the newborn.  While some retrospective 
studies have been published, there are no RCTs on the impact of these technologies 
upon newborn health and child development.   
The only Cochrane review on AH identified two studies out of 31 reporting on 
congenital anomalies and concluded that many unanswered questions remain about 
the perceived risks of the procedure, from embryo damage to chromosomal and 
congenital abnormalities (Carney et al., 2012).  
Conclusion 
IVF clinicians and scientists must recognise that appropriately powered, well-
designed, peer-reviewed RCTs, with a LBR outcome measure which goes on to 
report on child health, are the gold standard of evidenced-based medicine.  
Those advocating and recommending unproven procedures to their patients must 
ensure that they fully inform the patient of the evidence for its safety and 
effectiveness orally and in writing to ensure that people considering treatment using 
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adjunct therapies are in a position to make an informed decision.  It is also important 
that all procedures performed, including the adjunct treatments, are well documented 
and followed up. 
Regulators and professional bodies also have a role to play in ensuring that only 
suitable practices are used in the clinic. 
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